Compare EHTH & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHTH | SPRO |
|---|---|---|
| Founded | 1997 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.1M | 135.8M |
| IPO Year | 2006 | 2017 |
| Metric | EHTH | SPRO |
|---|---|---|
| Price | $3.48 | $2.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $7.00 | $5.00 |
| AVG Volume (30 Days) | ★ 296.6K | 227.1K |
| Earning Date | 02-25-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $542,951,000.00 | $40,549,000.00 |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $78.88 | ★ N/A |
| Revenue Growth | ★ 16.79 | N/A |
| 52 Week Low | $3.18 | $0.51 |
| 52 Week High | $11.36 | $3.22 |
| Indicator | EHTH | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 36.39 | 52.00 |
| Support Level | $3.43 | $2.31 |
| Resistance Level | $3.67 | $2.66 |
| Average True Range (ATR) | 0.20 | 0.09 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 4.35 | 34.78 |
eHealth Inc is a company involved in private health insurance marketplace with a technology and service platform that provides consumer engagement, education and health insurance enrollment solutions. The company operates its business in two segments: Medicare which provides health insurance plans and lesser extent ancillary products such as dental and vision insurance and hospital indemnity plans, to medicare eligible consumers; and Employer and Individual provides individual and family health insurance, and small business health insurance plans and Individual Coverage Health Reimbursement Arrangements. It derives maximum revenue from Medicare Segment. All of the company's revenue is from the United States. It also has a presence in China.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.